AstraZeneca PLC (AZN)vsOncology Institute Inc (TOI)
AZN
AstraZeneca PLC
$166.27
-1.05%
HEALTHCARE · Cap: $263.12B
TOI
Oncology Institute Inc
$5.13
+5.56%
HEALTHCARE · Cap: $512.91M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 11144% more annual revenue ($61.37B vs $545.76M). AZN leads profitability with a 17.0% profit margin vs -8.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
TOI
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+15.3%
Fair Value
$196.36
Current Price
$166.27
$30.09 discount
Margin of Safety
+22.9%
Fair Value
$3.40
Current Price
$5.13
$1.73 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Revenue surging 41.2% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -652.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.44 suggests the stock is reasonably priced for its growth.
Bull Case : TOI
The strongest argument for TOI centers on Revenue Growth, Debt/Equity. Revenue growth of 41.2% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : TOI
The primary concerns for TOI are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while TOI is a hypergrowth play — different risk/reward profiles.
TOI carries more volatility with a beta of 0.42 — expect wider price swings.
TOI is growing revenue faster at 41.2% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 45/100), backed by strong 17.0% margins. TOI offers better value entry with a 22.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Oncology Institute Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Oncology Institute Inc (ticker: TOI) is a leading healthcare organization focused on revolutionizing cancer care through its extensive network of specialized clinics and innovative treatment methodologies. By harnessing advanced technologies and personalized care strategies, the company aims to significantly improve patient outcomes while emphasizing clinical trials and partnerships with premier research institutions. Positioned to capitalize on the growing demand for advanced cancer therapies, TOI benefits from a solid pipeline and a wealth of oncology expertise, presenting a compelling investment opportunity within the dynamic healthcare landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?